Patient characteristics
| . | Overall . |
|---|---|
| N = 22 (%) . | |
| Median age, y (range) | 53.5 (36-81) |
| Sex | |
| Male | 15 (68%) |
| Female | 7 (32%) |
| Stage | |
| II | 1 (5%) |
| III | 4 (18%) |
| IV | 17 (77%) |
| WHO classification grade | |
| I/II | 16 (73%) |
| IIIa | 6 (27%) |
| ECOG performance score | |
| 0 | 13 (59%) |
| 1 | 9 (41%) |
| FLIPI score | |
| Low risk | 4 (18%) |
| Intermediate risk | 12 (55%) |
| High risk | 6 (27%) |
| Nodal sites | |
| ≤4 sites | 8 (36%) |
| >4 sites | 14 (64%) |
| Nodal size | |
| ≥5 cm | 11 (50%) |
| ≥7 cm | 6 (27%) |
| . | Overall . |
|---|---|
| N = 22 (%) . | |
| Median age, y (range) | 53.5 (36-81) |
| Sex | |
| Male | 15 (68%) |
| Female | 7 (32%) |
| Stage | |
| II | 1 (5%) |
| III | 4 (18%) |
| IV | 17 (77%) |
| WHO classification grade | |
| I/II | 16 (73%) |
| IIIa | 6 (27%) |
| ECOG performance score | |
| 0 | 13 (59%) |
| 1 | 9 (41%) |
| FLIPI score | |
| Low risk | 4 (18%) |
| Intermediate risk | 12 (55%) |
| High risk | 6 (27%) |
| Nodal sites | |
| ≤4 sites | 8 (36%) |
| >4 sites | 14 (64%) |
| Nodal size | |
| ≥5 cm | 11 (50%) |
| ≥7 cm | 6 (27%) |
ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; WHO, World Health Organization.